PapersPMID:39044170
European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - part 4: propranolol.
What moved
1 findingHow to read these marks →“We found high certainty evidence that propranolol increases the proportion of patients who discontinue due to adverse events compared to placebo with a risk difference of 0.02 (95% CI 0.00 to 0.03); absolute risk difference: 20 more per 1,000 (95% CI 0 to 30).”
- Study
- meta-analysis
- Participants
- 1,291
- Population
- Adults with migraine; meta-analysis of 20 randomized trials of oral propranolol versus placebo for migraine prophylaxis
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Adults with migraine, enrolled in randomized trials of oral propranolol versus placebo for migraine prophylaxis
- Participants
- 1,291
- Comparator
- not stated in the paper / placebo
- Duration
- not reported
- Endpoints measured
- 3
propranolol